Recombinant Ranibizumab Biosimilar antibody

Catalog No. ABIN7200657

The Humanized Monoclonal anti- antibody has been validated for FACS and in vivo. It is suitable to detect in samples from Human.

Quick Overview for Recombinant Ranibizumab Biosimilar antibody (ABIN7200657)

Target: Ranibizumab Biosimilar

Antibody Type: Recombinant Antibody

Fragment: Fab fragment

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details

Purpose: Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)

Specificity: The Fab protein ranibizumab specifically binds to the human VEGF-A.

Characteristics: The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss. Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.

Isotype: IgG1

Application Details

Application Notes: Functional assay, neutralization.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Storage: 4°C,-20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details

Target: Ranibizumab Biosimilar

Target Type: Biosimilar